4D Molecular Therapeutics Inc (NAS:FDMT)
$ 24.9 -0.25 (-0.99%) Market Cap: 1.29 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.12 GF Score: 58/100

4D Molecular Therapeutics Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 03:40PM GMT
Release Date Price: $10.23 (+2.20%)
Unidentified Analyst

Okay, everybody. Good morning. Welcome to our continuing session for the Bank of America Healthcare Conference.

Our next presenting company is 4D Molecular Therapeutics. Presenting for 4D this morning is CEO, David Kirn. David, good morning. Welcome to Bank of America's Conference.

David H. Kirn
4D Molecular Therapeutics, Inc. - Co-Founder, CEO, President & Director

Good morning. Thanks for having us.

Unidentified Analyst

So maybe we can start with an overview of the company, kind of what your differentiating points are? And then we can go into some more detailed questions if that works.

David H. Kirn
4D Molecular Therapeutics, Inc. - Co-Founder, CEO, President & Director

Yes, absolutely. So great to see everybody. I'm David Kirn, Cofounder and CEO of 4D Molecular Therapeutics. So we're a next-generation AAV gene therapy company. We leverage the power of directed evolution to create highly targeted and optimized products for a variety of both

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot